A trial looking at lenalidomide (Revlimid) for B cell chronic lymphocytic leukaemia that has responded to second line chemotherapy (The CONTINUUM Trial)

Overview

Cancer types:

Blood cancers, Chronic leukaemia, Chronic lymphocytic leukaemia (CLL), Leukaemia

Status:

Results

Phase:

Phase 3

Details

This trial compared lenalidomide with a dummy drug (placebo) to see if it stopped chronic lymphocytic leukaemia coming back after second line chemotherapy. It was for people with B cell chronic lymphocytic leukaemia that had responded to 2nd line treatment.

This trial started in 2009 and the results were published in 2017.

Recruitment start: 25 January 2009

Recruitment end: 9 October 2015